

# Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis

Kerstin Kling,<sup>1</sup> Cristina Domingo,<sup>2</sup> Christian Bogdan,<sup>3</sup> Steven Duffy,<sup>4</sup> Thomas Harder,<sup>1</sup> Jeremy Howick,<sup>4</sup> Jos Kleijnen,<sup>4</sup> Kevin McDermott,<sup>4</sup> Ole Wichmann,<sup>1</sup> Annelies Wilder-Smith,<sup>5,6</sup> and Robert Wolff<sup>4</sup>

<sup>1</sup>Immunization Unit, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany; <sup>2</sup>Center for International Health Protection, Robert Koch Institute, Berlin, Germany; <sup>3</sup>Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; <sup>4</sup>Kleijnen Systematic Reviews Ltd, York, United Kingdom; <sup>5</sup>Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany; and <sup>6</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

The duration of protection after a single dose of yellow fever vaccine is a matter of debate. To summarize the current knowledge, we performed a systematic literature review and meta-analysis. Studies on the duration of protection after 1 and  $\geq 2$  vaccine doses were reviewed. Data were stratified by time since vaccination. In our meta-analysis, we used random-effects models. We identified 36 studies from 20 countries, comprising more than 17 000 participants aged 6 months to 85 years. Among healthy adults and children, pooled seroprotection rates after single vaccination dose were close to 100% by 3 months and remained high in adults for 5 to 10 years. In children vaccinated before age 2 years, the seroprotection rate was 52% within 5 years after primary vaccination. For immunodeficient persons, data indicate relevant waning. The extent of waning of seroprotection after yellow fever vaccination depends on age and immune status at primary vaccination.

**Keywords.** yellow fever vaccine; duration of protection; risk group; immunodeficiency; systematic review.

Yellow fever (YF) is a vector-borne disease transmitted by mosquitoes of the *Aedes* and *Haemagogus* species. In 2020, 40 countries in Africa and South America were classified as endemic by the World Health Organization (WHO) [1]. The case fatality rate with the severe form of YF can reach 60% or more in persons with underlying diseases (such as diabetes mellitus) [2,3]. Each year, approximately 200 000 YF cases and 30 000 YF deaths occur worldwide [4]. Because no licensed drugs are available to treat YF, reduction of disease burden is exclusively accomplished through vaccination and vector control. Despite effective YF vaccines being available since the 1930s, outbreaks continue to occur, and the disease has spread into new areas during recent decades [5–7]. To date, it is unknown to what extent a lack of seroconversion (primary vaccine failure) and waning immunity (secondary vaccine failure) influence the individual risk of YF.

For many years, YF vaccine booster doses were recommended every 10 years for those at risk of exposure, including people

living in endemic countries and travellers. In 2013, WHO decided that a single dose of the YF vaccine is usually sufficient to confer life-long protection against YF, except for certain subpopulations such as persons with immunodeficiencies (eg, human immunodeficiency virus [HIV]). Accordingly, International Health Regulations were adapted in 2016 concerning validity of vaccination certificates. Since then, the sufficiency of a single dose for life-long protection has been questioned for various reasons [8–12]. To provide an up-to-date overview of the currently available data and knowledge, we performed a systematic review (SR) and meta-analysis on the duration of protection after vaccination against YF.

## METHODS

### Inclusion and Exclusion Criteria

We performed a SR in accordance with the methods recommended by Cochrane (formerly The Cochrane Collaboration) and the Centre for Reviews and Dissemination [13, 14]. Studies were selected for inclusion based on the following criteria:

- Population: People living in areas where YF is endemic (list of countries as defined by WHO) as well as travellers from non-endemic areas. Subgroups: children, adults ( $\geq 18$  years), older adults ( $\geq 60$  years), persons with any form of immunodeficiency, pregnant women, and persons who have received a vaccine against another flavivirus
- Intervention: Any full single dose of a licensed YF vaccine
- Comparators: Placebo, no vaccine, other vaccine, fractional dose or booster dose(s) of YF vaccine alone or with another

Received 08 April 2022; editorial decision 05 July 2022; published online 20 July 2022

Correspondence: K. Kling, Immunization Unit, Robert Koch Institute, Seestr. 10, 13353 Berlin, Germany (klingk@rki.de).

Clinical Infectious Diseases® 2022;75(12):2266–74

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com <https://doi.org/10.1093/cid/ciac580>

vaccine against another related viral disease (eg, Dengue fever, Japanese encephalitis)

- Outcomes: Proportion (%) of individuals with YF; proportion (%) of individuals with death from YF; seropositivity rates (eg, proportion [%] of individuals who are seropositive for neutralizing antibodies against YF)

We included randomized controlled trials (RCT), non-randomized (observational) studies with control groups, and prospective single-armed observational studies with  $\geq 50$  participants. Retrospective single arm studies, prospective single arm studies with  $< 50$  participants and case reports/series were excluded.

### Literature Search

We performed a systematic literature search in 15 databases (date of last search: November 12, 2021).

Search strategies combined relevant search terms comprising indexed keywords (eg, Medical Subject Headings) and free text terms appearing in the titles and/or abstracts of database records. Search terms were identified through discussion, by scanning background literature and “key articles” already known to the project team, and by browsing database thesauri. Searches were not limited by language, geographic location, publication status, or date of publication. The Embase search strategy was peer reviewed by a second information specialist. After removal of duplicates, 4800 records remained for further screening based on titles and abstracts. Full details of all search strategies are provided in [Supplementary Data](#).

Titles and abstracts identified through electronic database and web searching were independently screened by 2 reviewers. Subsequently, full texts were independently examined by 2 reviewers to determine whether they met the criteria for inclusion in the review (see [Supplementary Data](#) for studies excluded at this stage). Any discrepancies between reviewers were resolved through discussion or a third reviewer. The study selection process is detailed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [15].

### Data Extraction

Data extraction forms were individually designed and piloted using Microsoft Excel. Data extraction was performed by 1 reviewer and checked for accuracy by a second reviewer. Any discrepancies were resolved through discussion or through the intervention of a third reviewer. Where necessary and feasible, we requested additional information from the authors (details available upon request).

### Risk of Bias Assessment

Risk of bias in RCTs was assessed using the Cochrane risk of bias tool [16]. For assessment of nonrandomized studies we used the JBI (formerly Joanna Briggs Institute) checklist for nonrandomized experimental studies [17]. Assessments were

made by 2 reviewers independently and discrepancies were resolved through discussion or a third reviewer.

### Statistical Analyses

A narrative summary of all included studies was prepared in tabular form. Where available, separate data were described for subgroups.

To investigate the duration of vaccine-induced protection against YF, data were stratified according to the follow-up time period after vaccination:  $\leq 3$  months;  $> 3$  months to  $\leq 5$  years;  $> 5$  to  $\leq 10$  years;  $> 10$  to  $\leq 20$  years; and  $> 20$  years.

The outcome of interest was the proportion of people who were seropositive at a given time point postvaccination. The presence of neutralizing antibody titers  $\geq 1:10$  in the serum neutralization assay (which is the reference test for the detection of humoral immunity to YF) is an established correlate of protection in vaccinated individuals [18–20] for which equivalent efficacy of the 17D- and its 17DD-substrain has been extensively demonstrated [11, 21, 22].

Meta-analyses were performed using the `metaprop` command with exact 95% confidence intervals (95% CI) in R version 4.1.0. Study arms not containing a YF vaccine (eg, placebo) were excluded. If a study reported results at multiple time points for the same groups of participants, only the results for time points closest to 3 months, 5 years, 10 years, and 20 years, respectively, were included. All analyses have been grouped by the follow-up time period after vaccination. Results for the larger datasets (eg, for single-dose applications and endemic regions) were additionally grouped by study design and person subgroups (adults, children, persons with immunodeficiency).

This review was registered in PROSPERO (CRD42020223939).

## RESULTS

### Characteristics of the Included Studies

The systematic literature search revealed a total of 4800 records. Thirty-six studies [9, 21–55] (reported in 61 references) met the inclusion criteria (see [Supplementary Data](#)). These studies comprised 18 RCTs (reported in 32 references), 12 non-randomized comparative studies (non-RCTs, reported in 18 references), and 6 single-arm studies (reported in 11 references). For the study selection process, see PRISMA flow chart in [Supplementary Data](#).

The included studies were conducted during 1993–2019 and entailed about 10 000 participants in 11 endemic and about 7000 participants in 9 nonendemic countries, aged 6 months to 85 years (see [Table 1](#) for study characteristics). All but 1 study in children examined children who received their YF vaccination before the age of 2 years. Eight studies included participants with immunodeficiencies (including HIV, autoimmune diseases, organ transplantation recipients, and patients under immunosuppressive therapy for various reasons). The duration

**Table 1. Characteristics of Included Studies**

Study	Country (Endemic Region Y/N)	Subjects	n	Vaccine Specification	Specific Assay	Serology After YF Vaccination up to
<b>RCT</b>						
Asante et al., 2020 [23]	Ghana (Y)	Children	709	17D (Stamaril)	PRNT50	1 mo
Belmusto-Worm et al., 2005 [24]	Peru (Y)	Children	1107	17D (Arilvax, YF-VAX)	LNI	1 mo
Camacho et al., 2004 [21]	Brazil (N)	Adults	1087	17D (Amaril), 17DD	PRNT50	1 mo
Campi-Azevedo et al., 2014 [25]	Brazil (N)	Adults	590	17DD	PRNT50	1 y
Chan et al., 2016 [26]	Singapur (N)	Adults	70	17D (Stamaril)	PRNT50	1 mo
Collaborative Group, 2015 [22]	Brazil (Y)	Children	1966	17D (Amaril), 17DD	PRNT50	1 mo
Coursaget et al., 1995 [27]	Senegal (Y)	Children	220	17D (Amaril)	PRNT90	1 mo
Edupuganti et al., 2012 [28]	US (N)	Adults	40	17D (YF-VAX)	PRNT90	3 mo
Guirakhoo et al., 2006 [29]	US (N)	Adults	42	17D (YF-VAX)	LNI	3 y
Juan-Giner et al., 2021 [30]	Uganda, Kenya (Y)	Adults	960	17D (different vaccines), 17DD	PRNT50, PRNT90; noninferiority with PRNT50	1 y
Lang et al., 1999 [31]	UK (N)	Adults	185	17D (Stamaril, Arilvax)	PRNT80	1 mo
Lopez et al., 2016 [32]	Colombia and Peru (Y)	Children	792	17D (Stamaril)	PRNT50	1 mo
Monath et al., 2002 [33]	US (N)	Adults	1440	17D (Arilvax, YF-VAX)	LNI	1 mo
Nasveld et al., 2010 [34]	US (N)	Adults	90	17D (Stamaril)	PRNT50	6 mo
NOVARTIS, 2012 [35]	Czech Republic, Germany (N)	Adults	101	17D (Stamaril)	NR	1 mo
Osei-Kwasi et al., 2001 [36]	Ghana (Y)	Children	384	17D (Amaril)	microNT	3 mo
Roukens et al., 2008 [37]	Netherlands (N)	Adults	175	17D (Stamaril)	PRNT80	1 y
Stefano et al., 1999 [38]	Brazil (Y)	Children	294	17DD	PRNT50	1 mo
<b>Non-RCT</b>						
Avelino-Silva et al., 2016 <sup>a</sup> [39]	Brazil (N)	Adults with HIV	63	NR	PRNT50	1 y
Avelino-Silva et al., 2016 <sup>a</sup> [40]	Brazil (N)	Adults with HIV	92	17DD	PRNT50	11 y
Burkhard et al., 2020 [41]	Switzerland (N)	Adults with immunosuppressive therapy	75	NR	PRNT90/PRNT80	31 y
Campi-Azevedo et al., 2016 [9]	Brazil (Y)	Adults	171	17DD	PRNT50	13 y
Collaborative Group, 2019 [42]	Brazil (Y)	Adults	323	17DD	PRNT50	> 10 y
Collaborative Group, 2019 [43]	Brazil (Y)	Adults	326	17DD	PRNT50	30 y
De Verdere et al., 2018 [44]	France (N)	Adults with HIV	71	17D (Stamaril)	PRNT80	1 y
Kerneis et al., 2013 [45]	France (N)	Adults under corticosteroids	131	17D (Stamaril)	PRNT	3 mo
Michel et al., 2015 [46]	Senegal, French Guyana (Y)	Children	284	17D (different vaccines)	PRNT90	2 mo
Project RETRO-CI, 1997 [47]	Ivory Coast (Y)	Children with HIV	75	17D (Amaril)	PRNT	> 5 mo
Roukens et al., 2011 <sup>b</sup> [48]	Netherlands (N)	Adults	58	17D (Stamaril)	PRNT80	10 y
Valim et al., 2020 [49]	Brazil (Y)	Adults with autoimmune diseases	278	17DD	PRNT50	1 mo
<b>Single arm studies</b>						
Campi-Azevedo et al., 2019 [50]	Brazil (Y)	Children	673	17DD	PRNT50	10 y
Domingo et al., 2019 [51]	Ghana, Mali (Y)	Children	1023	17D (Stamaril), 17DD	microNT	6 y
Idoko et al., 2020 [52]	Gambia, Mali (Y)	Children	481	17D (Stamaril), 17DD	microNT	6 y
Jia et al., 2019 [53]	China (N)	Adults	2411	Based on 17D (produced in China)	PRNT50	11 y
Kareko et al., 2018 [54]	US (N)	Adults	92	17D (YF-VAX)	PRNT90	14 y
Veit et al., 2017 [55]	Switzerland (N)	Adults with HIV	247	17D (different vaccines)	PRNT90	10 y

Abbreviations: LNI, log<sub>10</sub> Neutralization Index; microNT, microNeutralization Test; N, no; NR, not reported; PRNT, Plaque Reduction Neutralization Test; Y, yes; YF, yellow fever; mo, month(s); y, year(s).

<sup>a</sup>Personal communication with Dr Avelino-Silva confirmed that “the study populations in these 2 publications have some overlap but were not exactly the same.” Participants in Avelino-Silva 2016 [40] were previously vaccinated and referred for booster YF vaccine while some participants in Avelino-Silva 2016 [39] were previously included in Avelino-Silva 2016 [40] but some were vaccinated for the first time. In this systematic review, the publications were handled as 2 separate studies.

<sup>b</sup>Updated information is available in Rosenstein et al. [56].

of protection beyond 3 months after YF vaccination was analyzed in 20 studies. All included studies reported the titers of detectable neutralizing antibodies as surrogate markers for protection. None of the studies reported the proportion of individuals with clinical endpoints such as YF or death from YF.

#### Risk of Bias Assessment

Six of the 36 included studies (4 RCTs and 2 nonrandomized studies) had a low risk of bias (RoB), whereas RoB was high in 23 studies (10 RCTs and 13 nonrandomized studies). The remaining 7 studies were of unclear RoB (Supplementary Data).

#### Protection After Single Dose of YF Vaccine

Up to 3 months: A total of 29 studies investigated the protection up to 3 months after a single dose of YF vaccine. In all groups with healthy individuals (adults [16 studies], children [10 studies]), pooled seroprotection rates were close to 100%. In persons with immunodeficiency (3 studies), pooled seroprotection rate was 92% (Table 2 and Supplementary Data).

>3 months up to 5 years: Protection up to 5 years was addressed in 15 studies. In adults (8 studies), the pooled seroprotection rate remained as high as 97%. In contrast, the seroprotection rate was 52% in children (3 studies), with all 3 studies being conducted in endemic countries. In persons with immunodeficiency, the pooled seroprotection rate was slightly lower than for the preceding time interval (86%; 4 studies; Table 2 and Supplementary Data).

>5 years up to 10 years: Eleven studies addressed protection up to 10 years. In adults from both endemic and nonendemic countries, seroprotection rates were 88% (6 studies). In children, the respective value was 54% (3 studies in endemic settings). Two studies in persons with immunodeficiency in nonendemic settings showed a pooled seroprotection rate of 75% (Table 2 and Supplementary Data).

>10 years up to 20 years: Protection up to 20 years was evaluated in 5 studies. In 4 studies (3 from endemic countries, 1 from a nonendemic country), the pooled seroprotection rate was 71% for healthy adults. No studies were conducted in children. The only study in immunodeficient persons in a nonendemic country showed a seroprotection rate of 62% (Table 2 and Supplementary Data).

>20 years: The only study for this period was performed in immunodeficient adults in a nonendemic setting and showed a seroprotection rate of 94% in 16 of 17 persons who had been vaccinated before immunosuppressive therapy (Table 2 and Supplementary Data). Supplementary Data 6 includes all forest plots. The allocation of the forest plots is listed in the first column of Tables 2, 3, and 4, respectively.

#### Protection After 1 Booster Dose of YF Vaccine

Up to 3 months, seroprotection rates were 98% in adults and 100% in patients with immunodeficiency. Between 3 months

and 5 years after the booster dose, 1 study in an endemic and 1 in a nonendemic setting reported a pooled seroprotection rate of 92%. Up to 10 years after the booster dose, 3 studies in adults resulted in a pooled seroprotection rate of 88%.

Two studies in adults, one of which was performed in an endemic country, reported a pooled seroprotection rate of 86% for 10 to 20 years after booster dose.

For protection >20 years after booster dose, a study in immunodeficient persons receiving corticosteroid therapy showed a seroprotection rate of 88% (Table 3 and Supplementary Data).

In children, none of the studies met the inclusion criteria.

#### Protection After 2 or More Booster Doses of YF Vaccine

In 2 studies that investigated the protection from 3 months to 5 years after multiple booster doses in adults a pooled seroprotection rate of 90% was reported. For >10 years, 1 study that was performed in a nonendemic setting with patients receiving corticosteroid therapy, demonstrated a seroprotection rate of 100%. The participants had their first YF vaccination before the onset of immunosuppression (Table 4 and Supplementary Data).

#### Subgroup Analysis: Protection in Immunocompromised Persons

In persons with HIV, reduced antibody levels and a faster waning of YF immunity within 10 years were found compared with healthy controls, especially in patients with unsuppressed HIV RNA [44, 47, 55]. In persons with autoimmune diseases, seroprotection rates ranged between 73% and 85% 1 month after primary vaccination, depending on the underlying disease [49].

Another study in patients with autoimmune diseases examined the duration of immunity after 1 or more vaccine doses. All seronegative participants had only received a single YF vaccine dose. Those with 2 doses (or more) were seropositive for up to 33 years after the last dose [41] (Tables 2, 3, and 4).

#### Subgroup Analysis: Protection in Persons Aged >60 Years

Two studies reported on persons >60 years [48, 56]. A group of 28 persons was followed up 10 years after having received their first dose between 60 and 80 years of age. All of the 22 participants that could be contacted at the end of the observation period maintained a protective titer 10 years after primary vaccination [56].

#### Subgroup Analysis: Cross-reactive Antibodies Against Other Flavivirus

In 1 study with cross-reactive antibodies from a prior vaccination against Japanese encephalitis, an enhanced YF immunogenicity was detected after YF vaccination [26]. Cross-reactive antibodies facilitated immune cell interactions and provoked greater pro-inflammatory responses.

## DISCUSSION

This systematic review shows that the YF vaccine confers high rates of seroprotection within 3 months after primary

**Table 2. Protection After Single Dose of YF Vaccine: Results of the Meta-analysis**

Forest Plot	Population	n Studies	n Data Points	n Subjects	Effect Estimate	95% CI	I <sup>2</sup>
<b>≤3 mo</b>							
001	Adults	16	27	3115	0.98	0.97–0.98	64%
002	Endemic	4	7	587	0.97	0.95–0.99	0%
003	Nonendemic	12	20	2528	0.98	0.97–0.99	68%
004	Children	10	21	5654	0.94	0.90–0.96	92%
005	Endemic	10	21	5654	0.94	0.90–0.96	92%
006	Nonendemic	0	0	0	N/A	N/A	N/A
007	Immunodeficient	3	3	208	0.92	0.65–0.98	66%
008	Endemic	1	1	160	0.78	0.71–0.84	N/A
009	Nonendemic	2	2	48	0.98	0.84–1.00	0%
<b>&gt;3 mo to ≤5 y</b>							
010	Adults	8	13	790	0.97	0.95–0.98	0%
011	Endemic	3	6	514	0.98	0.95–0.99	0%
012	Nonendemic	5	7	276	0.96	0.93–0.98	0%
013	Children	3	4	1208	0.52	0.33–0.71	96%
014	Endemic	3	4	1208	0.52	0.33–0.71	96%
015	Nonendemic	0	0	0	N/A	N/A	N/A
016	Immunodeficient	4	4	198	0.86	0.31–0.99	91%
017	Endemic	1	1	18	0.17	0.04–0.41	N/A
018	Nonendemic	3	3	180	0.94	0.77–0.99	56%
<b>&gt;5 y to ≤10 y</b>							
019	Adults	6	7	267	0.88	0.78–0.93	53%
020	Endemic	2	2	45	0.88	0.75–0.95	0%
021	Nonendemic	4	5	222	0.89	0.74–0.96	63%
022	Children	3	3	1044	0.54	0.37–0.70	97%
023	Endemic	3	3	1044	0.54	0.37–0.70	97%
024	Nonendemic	0	0	0	N/A	N/A	N/A
025	Immunodeficient	2	2	67	0.75	0.64–0.84	0%
026	Endemic	0	0	0	N/A	N/A	N/A
027	Nonendemic	2	2	67	0.75	0.64–0.84	0%
<b>&gt;10 y to ≤20 y</b>							
028	Adults	4	4	231	0.71	0.62–0.79	36%
029	Endemic	3	3	193	0.74	0.63–0.82	43%
030	Nonendemic	1	1	38	0.63	0.46–0.78	N/A
031	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
034	Immunodeficient	1	1	8	0.62	0.24–0.91	N/A
035	Endemic	0	0	0	N/A	N/A	N/A
036	Nonendemic	1	1	8	0.62	0.24–0.91	N/A
<b>&gt;20 y</b>							
037	Adults	1	1	1	0.00	0.00–0.98	N/A
038	Endemic	0	0	0	N/A	N/A	N/A
039	Nonendemic	1	1	1	0.00	0.00–0.98	N/A
040	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
043	Immunodeficient	1	1	17	0.94	0.71–1.00	N/A
044	Endemic	0	0	0	N/A	N/A	N/A
045	Nonendemic	1	1	17	0.94	0.71–1.00	N/A

Abbreviations: CI, confidence interval; N/A, not available; YF, yellow fever; mo, months; y, years.

<sup>a</sup>No data.

vaccination. After a single vaccine dose, reduced seroprotection rates were observed 5 and 10 years after vaccination of healthy adults and 3 months to 5 years after vaccination of children. There is only scarce data on the persistence of humoral immunity beyond 10 years after a single YF vaccine dose. Beyond 20 years, no studies have been published in healthy adults. In

immunodeficient persons, only limited data for different groups are available, which make general statements difficult. However, our subgroup analysis allows the conclusion that waning occurs in all groups examined. In the majority of studies, waning was more pronounced in immunodeficient persons than in healthy adults.

**Table 3. Protection After 1 Booster Dose of YF Vaccine: Results of the Meta-analysis**

Forest Plot	Population	<i>n</i> Studies	<i>n</i> Data Points	<i>n</i> Subjects	Effect Estimate	95% CI	<i>I</i> <sup>2</sup>
<b>≤3 mo</b>							
046	Adults	2	2	64	0.98	0.89–1.00	0%
047	Endemic	1	1	45	1.00	0.92–1.00	N/A
048	Nonendemic	1	1	19	1.00	0.82–1.00	N/A
049	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
052	Immunodeficient	1	1	11	1.00	0.72–1.00	N/A
053	Endemic	0	0	0	N/A	N/A	N/A
054	Nonendemic	1	1	11	1.00	0.72–1.00	N/A
<b>&gt;3 mo to ≤5 y</b>							
055	Adults	2	2	62	0.92	0.82–0.97	0%
056	Endemic	1	1	47	0.91	0.80–0.98	N/A
057	Nonendemic	1	1	15	1.00	0.78–1.00	N/A
058	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
061	Immunodeficient <sup>a</sup>	0	0	0	N/A	N/A	N/A
<b>&gt;5 y to ≤10 y</b>							
064	Adults	3	3	258	0.88	0.84–0.92	0%
065	Endemic	2	2	249	0.88	0.83–0.91	0%
066	Nonendemic	1	1	9	1.00	0.66–1.00	N/A
067	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
070	Immunodeficient <sup>a</sup>	0	0	0	N/A	N/A	N/A
<b>&gt;10 y to ≤20 y</b>							
073	Adults	2	2	17	0.86	0.61–0.96	0%
074	Endemic	1	1	12	0.83	0.52–0.98	N/A
075	Nonendemic	1	1	5	1.00	0.48–1.00	N/A
076	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
079	Immunodeficient <sup>a</sup>	0	0	0	N/A	N/A	N/A
<b>&gt;20 y</b>							
082	Adults <sup>a</sup>	0	0	0	N/A	N/A	N/A
085	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
088	Immunodeficient	1	1	40	0.88	0.73–0.96	N/A
089	Endemic	0	0	0	N/A	N/A	N/A
090	Nonendemic	1	1	40	0.88	0.73–0.96	N/A

Abbreviations: CI, confidence interval; N/A, not available; YF, yellow fever; mo, months; y, years.

<sup>a</sup>No data.

Only very limited data exist on the effects of booster vaccinations. For the time span beyond 20 years, either after a single YF vaccine dose or after booster doses, the only available data are derived from 1 study with immunodeficient persons. Because of the small sample size and a wide 95% CI, the results are difficult to interpret [41].

Our data revealed no epidemiologically relevant differences between endemic and nonendemic settings, suggesting that natural boosters in endemic settings are either rare or do not play a major role in maintaining protection.

The Strategic Advisory Group of Experts on Immunization, the principal advisory group to the WHO for vaccines and immunization, concluded in 2013 that YF booster doses are not needed for lifelong protection against YF in immunocompetent persons. The conclusion was based on an SR published in 2013 by Gotuzzo et al. [57]. However, this SR has been criticized for its methodological weaknesses. Other experts questioned the development of long-term protective immunity in a

considerable proportion of those vaccinated with only 1 dose [8, 10, 12, 58]. The SR by Gotuzzo et al. mainly relies on retrospective cohort and small observational studies including case reports.

Since the data cut of the SR by Gotuzzo et al. [57], 23 additional studies have been published that were incorporated in our meta-analysis. To ascertain high-quality evidence, we excluded retrospective studies, case reports, and case series. Prospective single-arm studies were only accepted if they comprised ≥50 participants. Moreover, we included studies with different entities of immunodeficiency, such as patients seropositive for HIV (adults and children), patients with autoimmune diseases and organ transplantation recipients.

In persons with immunodeficiency, seroprotection after primary vaccination was only slightly lower than in healthy persons, but appeared to wane faster. Some countries recommend booster doses for patients with some but not all conditions leading to immunodeficiency [59]. The analysis of the

**Table 4. Protection After 2 or More Booster Doses of YF Vaccine: Results of the Meta-analysis**

Forest Plot	Population	<i>n</i> Studies	<i>n</i> Data Points	<i>n</i> Subjects	Effect Estimate	95% CI	<i>I</i> <sup>2</sup>
<b>≤3 mo</b>							
092	Adults <sup>a</sup>	0	0	0	N/A	N/A	N/A
095	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
097	Immunodeficient <sup>a</sup>	0	0	0	N/A	N/A	N/A
<b>&gt;3 mo to ≤5 y</b>							
100	Adults	2	2	14	0.90	0.62–0.98	0%
101	Endemic	2	2	14	0.90	0.62–0.98	0%
102	Nonendemic	0	0	0	N/A	N/A	N/A
103	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
106	Immunodeficient <sup>a</sup>	0	0	0	N/A	N/A	N/A
<b>&gt;5 y to ≤10 y</b>							
109	Adults <sup>a</sup>	0	0	0	N/A	N/A	N/A
112	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
115	Immunodeficient <sup>a</sup>	0	0	0	N/A	N/A	N/A
<b>&gt;10 y to ≤20 y</b>							
118	Adults <sup>a</sup>	0	0	0	N/A	N/A	N/A
121	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
124	Immunodeficient	1	1	2	1.00	0.16–1.00	N/A
125	Endemic	0	0	0	N/A	N/A	N/A
126	Nonendemic	1	1	2	1.00	0.16–1.00	N/A
<b>&gt;20 y</b>							
127	Adults <sup>a</sup>	0	0	0	N/A	N/A	N/A
130	Children <sup>a</sup>	0	0	0	N/A	N/A	N/A
133	Immunodeficient	1	1	3	1.00	0.29–1.00	N/A
134	Endemic	0	0	0	N/A	N/A	N/A
135	Nonendemic	1	1	3	1.00	0.29–1.00	N/A

Abbreviations: CI, confidence interval; N/A, not available; YF, yellow fever; mo, months; y, years.

<sup>a</sup>No data.

various diseases associated with immunodeficiency supports to extend this recommendation to other patient groups with immunodeficiencies, provided that there are no contraindications for a YF vaccination of the individual.

Persons aged 60 years and older often exhibit immunosenescence, which increases with age but also depends on other factors such as comorbidities. Although in one study all analyzed participants aged >60 years still showed a protective YF titer 10 years after primary vaccination, the studied cohort was too small to draw firm conclusions [56].

The only study that measured antibodies against Japanese encephalitis [26] indicated a potential impact of antibodies cross-reactive with the YF virus, but the duration and relevance of this cross-reactivity remains uncertain. In endemic settings with high Dengue seropositivity, preexisting antibodies against dengue might lead to an overestimation of the seroprotection against YF.

One reason for no longer recommending routine booster doses was the extremely low number of reported YF vaccine failures. This rationale can be misleading because vaccine failures can only be detected on exposure of the vaccinated person to the YF virus as it occurs during outbreaks or in highly

endemic sylvatic areas in Latin America. In addition, an underestimation of vaccine failures can result from insufficient local surveillance, case detection, and reporting, especially in endemic countries in Africa, where 90% of all YF cases occur [4].

In Africa, reliable laboratory diagnostics are developing and recent examples, such as the YF outbreak in Uganda, might also show secondary vaccine failures [60].

For control and elimination of YF, it is crucial to improve the epidemiological surveillance not only for vaccine failures, but also for outbreaks [61].

#### Strengths and Limitations

Our review has several strengths. It adheres to rigorous methods recommended by relevant bodies such as Cochrane and the Centre for Reviews and Dissemination. With the last literature search performed in November 2021, our review reflects the current state of the evidence. With our meta-analysis, we provide numerical estimates for protection at different time points after vaccination. High risk of bias and statistical heterogeneity of some of the included studies limit the ability to generate firm implications. The limitations associated with a functional assay and the variability among protocols represent a challenge for the

comparison of results. Because serum neutralization assays are usually only carried out in reference or specialized laboratories for the assessment of the immune response in vaccinated individuals, they certainly can provide a robust estimation on the presence of protective immunity against YF. Although we excluded prospective studies with fewer than 50 participants, for some study arms the number of subjects was too small to draw firm conclusions, which particularly applies to the studies with immunodeficient persons. Based on our data, it is not possible to make definitive statements on the necessity and impact of 1 or several YF booster doses in immunodeficient patients.

## CONCLUSIONS

A single dose of YF vaccine confers high levels of immunity (as measured by seroprotection rates) in healthy adults for up to 10 years, after which waning occurs, thereby increasing the risk for secondary vaccine failures. The extent to which immunity wanes depends on the age and immune status at primary vaccination.

## Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

## Notes

**Author contributions.** K. K., T. H., J. K., and R. W. developed the protocol and S. D. developed the search strategy. K. K., T. H., C. D., and O.W. conceptualized the study, developed the PICO question, and finalized the manuscript. K. K., S. D., J. H., J. K., K. M., and R. W. reviewed full-text articles and abstracted the data. R. W. and K. K. performed the analysis. K. K., C. D., and T. H. checked data extraction. K. K. wrote the first draft of the manuscript. C. B. provided immunological expertise and contributed to the writing of the paper. A. W. S. contributed to the interpretation of data and writing of the final manuscript. T. H. supervised study conduct, and all authors reviewed the manuscript for final revisions before submission.

**Acknowledgments.** The authors thank Gerd Burchard, Annette Chalker, Annika Falman, Debra Fayter, Carol Forbes, Thomas Ledig, Thomas Mertens, Marianne Röbl-Mathieu, Jonas Schmidt-Chanasit, Ursula Wiedermann-Schmidt, and Gill Worthy for their valuable contribution to the content.

**Financial support.** This work was supported by internal funding from the Center for International Health Protection (ZIG), Robert Koch Institute, Berlin, Germany.

**Potential conflicts of interest.** C. D. reports an unpaid position as Chairman of the WHO EYE (Eliminating Yellow Fever Epidemics) Laboratory Technical Working Group. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

1. WHO. Countries with risk of yellow fever transmission and countries requiring yellow fever vaccination (July 2020). Available at: [https://www.who.int/publications/m/item/countries-with-risk-of-yellow-fever-transmission-and-countries-requiring-yellow-fever-vaccination-\(july-2020\)](https://www.who.int/publications/m/item/countries-with-risk-of-yellow-fever-transmission-and-countries-requiring-yellow-fever-vaccination-(july-2020)). Accessed April 4, 2021.

2. Monath TP, Vasconcelos PF. Yellow fever. *J Clin Virol* **2015**; 64:160–73.
3. Ho YL, Joelsons D, Leite GFC, et al. Severe yellow fever in Brazil: clinical characteristics and management. *J Travel Med* **2019**; 26:taz040.
4. WHO. Vaccines and vaccination against yellow fever. WHO position paper – June 2013. *Wkly Epidemiol Rec* **2013**; 88:269–83.
5. Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination strategies. *Trop Dis Travel Med Vaccines* **2020**; 6:1.
6. Rezende IM, Sacchetto L, Munhoz de Mello E, et al. Persistence of yellow fever virus outside the Amazon basin, causing epidemics in southeast Brazil, from 2016 to 2018. *PLoS Negl Trop Dis* **2018**; 12:e0006538.
7. Zhao S, Musa SS, Hebert JT, et al. Modelling the effective reproduction number of vector-borne diseases: the yellow fever outbreak in Luanda, Angola 2015–2016 as an example. *PeerJ* **2020**; 8:e8601.
8. Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. *Expert Rev Vaccines* **2016**; 15:1519–33.
9. Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. *Hum Vaccin Immunother* **2016**; 12:491–502.
10. Plotkin SA. Ten yearly yellow fever booster vaccinations may still be justified. *J Travel Med* **2018**; 25(1).
11. Staples JE, Barrett ADT, Wilder-Smith A, Hombach J. Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. *npj Vaccines* **2020**; 5:54.
12. Vasconcelos PF. Single shot of 17D vaccine may not confer life-long protection against yellow fever. *Mem Inst Oswaldo Cruz* **2018**; 113:135–7.
13. Centre for Reviews and Dissemination. Systematic Reviews: CRD's guidance for undertaking reviews in health care. Available at: <http://www.york.ac.uk/inst/crd/SysRev/ISSLI/WebHelp/SysRev3.htm>. Accessed 08 07 2021.
14. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). John Wiley & Sons; **2019**.
15. PRISMA Group. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. Available at: <http://prisma-statement.org/>. Accessed October 12, 2020.
16. Sterne JAC, Savović J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**; 366:l4898.
17. Joanna Briggs Institute. Critical appraisal tools for use in JBI systematic reviews: checklist for case series. Available at: <https://joannabriggs.org/critical-appraisal-tools>. Accessed 12 10 2020.
18. WHO. Correlates of vaccine-induced protection: methods and implications. Available at: [https://apps.who.int/iris/bitstream/handle/10665/84288/WHO\\_IVB\\_13.01\\_eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/84288/WHO_IVB_13.01_eng.pdf). Accessed March 17, 2022.
19. Plotkin SA. Correlates of protection induced by vaccination. *Clin Vaccine Immunol* **2010**; 17:1055–65.
20. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. *Appl Microbiol* **1973**; 25: 539–44.
21. Camacho LA, Freire Mda S, Leal Mda L, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. *Rev Saude Publica* **2004**; 38:671–8.
22. Collaborative Group for Studies of Yellow Fever Vaccine. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine–23 months old. *Mem Inst Oswaldo Cruz* **2015**; 110: 771–80.
23. Asante KP, Ansong D, Kaali S, et al. Immunogenicity and safety of the RTS, S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: a phase IIb, multi-center, non-inferiority, randomized, open, controlled trial. *Vaccine* **2020**; 38:3411–21.
24. Belmusto-Worn VE, Sanchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. *Am J Trop Med Hyg* **2005**; 72:189–97.
25. Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. *BMC Infect Dis* **2014**; 14:391.
26. Chan KR, Wang X, Saron WAA, et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. *Nat Microbiol* **2016**; 1: 16164.
27. Coursaget P, Fritzell B, Blondeau C, Saliou P, Diop-Mar I. Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines. *Vaccine* **1995**; 13:109–11.
28. Edupuganti S, Eidex RB, Keyserling H, et al. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with



- immune globulin or placebo: comparative viremia and immunogenicity. *Am J Trop Med Hyg* **2013**; 88:172–7.
29. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. *Hum Vaccin* **2006**; 2:60–7.
  30. Juan-Giner A, Kimathi D, Grantz KH, et al. Immunogenicity and safety of fractional doses of yellow fever vaccines: A randomised, double-blind, non-inferiority trial. *Lancet* **2021**; 397:119–27.
  31. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. *Am J Trop Med Hyg* **1999**; 60:1045–50.
  32. Lopez P, Lanata CF, Zambrano B, et al. Immunogenicity and safety of yellow fever vaccine (Stamaril) when administered concomitantly with a tetravalent Dengue vaccine candidate in healthy toddlers at 12–13 months of age in Colombia and Peru: a randomized trial. *Pediatr Infect Dis J* **2016**; 35:1140–7.
  33. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. *Am J Trop Med Hyg* **2002**; 66:533–41.
  34. Nasveld PE, Marjason J, Bennett S, et al. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. *Hum Vaccin* **2010**; 6:906–14.
  35. Novartis Vaccines and Diagnostics S.r.l. Study to evaluate the safety and immunogenicity of travel vaccines when administered concomitantly with meningococcal ACWY conjugate vaccine in healthy adults. *ICTRP* **2011**; 11:1056–9.
  36. Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK. Antibody response to 17D yellow fever vaccine in Ghanaian infants. *Bull World Health Organ* **2001**; 79:1056–9.
  37. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. *PLoS One* **2008**; 3:e1993.
  38. Stefano I, Sato HK, Pannuti CS, et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. *Vaccine* **1999**; 17:1042–6.
  39. Avelino-Silva VI, Miyaji KT, Hunt PW, et al. CD4/CD8 Ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients. *PLoS Negl Trop Dis* **2016**; 10:e0005219.
  40. Avelino-Silva VI, Miyaji KT, Mathias A, et al. CD4/CD8 Ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients. *J Acquir Immune Defic Syndr* **2016**; 71:189–95.
  41. Burkhard J, Ciurea A, Gabay C, et al. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. *Vaccine* **2020**; 38:3610–7.
  42. Collaborative group for studies on yellow fever vaccines. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine. *Vaccine* **2019**; 37:5129–35.
  43. Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JG, et al. 17DD Yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil. *Emerg Infect Dis* **2019**; 25:1511–21.
  44. de Verdier NC, Durier C, Samri A, et al. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. *AIDS* **2018**; 32:2291–9.
  45. Kerneis S, Launay O, Ancelle T, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. *Arthritis Care Res (Hoboken)* **2013**; 65:1522–8.
  46. Michel R, Berger F, Ravelonarivo J, et al. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines? *Vaccine* **2015**; 33:2301–6.
  47. Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. *Pediatr Infect Dis J* **1997**; 16:1177–9.
  48. Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. *PLoS One* **2011**; 6:e27753.
  49. Valim V, Machado K, Miyamoto ST, et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: a prospective non-interventional study. *Front Immunol* **2020**; 11:1382.
  50. Campi-Azevedo AC, Reis LR, Peruhype-Magalhaes V, et al. Short-lived immunity after 17DD yellow fever single dose indicates that booster vaccination may be required to guarantee protective immunity in children. *Front Immunol* **2019**; 10:2192.
  51. Domingo C, Fraissinet J, Ansah PO, et al. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. *Lancet Infect Dis* **2019**; 19:1363–70.
  52. Idoko OT, Domingo C, Tapia MD, et al. Serological protection 5–6 years post vaccination against yellow fever in African infants vaccinated in routine programmes. *Front Immunol* **2020**; 11:577751.
  53. Jia Q, Jia C, Liu Y, et al. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa. *Antiviral Res* **2019**; 162:1–4.
  54. Kareko BW, Booty BL, Nix CD, et al. Persistence of neutralizing antibody responses among yellow fever virus 17D vaccinees living in a nonendemic setting. *J Infect Dis* **2020**; 221:2018–25.
  55. Veit O, Domingo C, Niedrig M, et al. Long-term immune response to yellow fever vaccination in human immunodeficiency virus (HIV)-infected individuals depends on HIV RNA suppression status: implications for vaccination schedule. *Clin Infect Dis* **2018**; 66:1099–108.
  56. Rosenstein MD, de Visser AW, Visser LG, Roukens AHE. Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: a 10-year follow-up study. *J Travel Med* **2021**; 28:taab126.
  57. Gotuzzo E, Yactayo S, Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. *Am J Trop Med Hyg* **2013**; 89:434–44.
  58. Visser LG, Veit O, Chen LH. Waning immunity after single-dose yellow fever vaccination: who needs a second shot? *J Travel Med* **2019**; 26:tay134.
  59. Centres for Disease Control and Prevention. Grading of recommendations, assessment, development, and evaluation (GRADE) for yellow fever vaccine booster doses. Available at: <https://www.cdc.gov/vaccines/acip/recs/grade/yf-vac-boost.html>. Accessed March 19, 2022.
  60. WHO. Weekly bulletin on outbreaks and other emergencies. Available at: <https://apps.who.int/iris/bitstream/handle/10665/352663/OEW13-2127032022.pdf>. Accessed April 3, 2022.
  61. Petraglia TCMB, Farias PMCM, Sá GRSE, Santos EMD, Conceição DAD, Maia MLS. Vaccine failures: assessing yellow fever, measles, varicella, and mumps vaccines. *Cadernos de saude publica* **2020**; 36:e00008520.